Through partnerships such as this, FDNA's next-generation phenotyping technologies that capture, structure, and interpret complex physiological information, are used in analyzing patient clinical data and next-generation sequencing data.
FDNA is the developer of Face2Gene, a clinical suite of phenotyping applications that facilitates comprehensive and precise genetic evaluations.
The concentrations of circulating fDNA were then analyzed along with pertinent clinical information to better understand the dynamics of circulating fDNA after TOP.
We measured fDNA in maternal plasma and the POC solution by real-time PCR amplification using a Perkin-Elmer Applied Biosystems 7700 Sequence Detector (Applied Biosystems).
The Wilcoxon signed-rank test was used to assess the difference in median fDNA concentrations between pre- and posttermination samples.
- Vanderbilt University Medical Center will integrate of Boston, Massachusetts-based phenotypic applications developer FDNA's Face2Gene suite of applications into the Vanderbilt Center for Undiagnosed Diseases workflow to evaluate difficult-to-diagnose patients in their role as part of the National Institutes of Health Undiagnosed Disease Network (UDN), the company said.
Vanderbilt University Medical Center is the first of many sites that have approached FDNA to use Face2Gene for UDN cases.
has launched integration between its secure AmbryPort 2.0 clinician ordering platform and FDNA's Face2Gene suite of applications, the company said.
Part of a commitment towards making large-scale genetic testing more affordable and available, Ambry Genetics' collaboration with FDNA will increase clinicians' abilities to quickly diagnose and treat patients, while accelerating the rate of scientific discoveries in rare diseases.
- Framingham, Massachusetts-based genomic diagnostics services provider Variantyx is integrating its clinical whole genome testing pipeline with Boston, Massachusetts-based phenotypic applications developer FDNA's Face2Gene suite of applications, the company said.
"By integrating FDNA's technology within the Genomic Intelligence platform, a more complete phenotypic picture is provided, helping prioritize genetic variants that may have otherwise been missed," said Variantyx, CEO Haim Neerman.